Send me real-time posts from this site at my email

BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know

BioTelemetry (BEAT) closed the most recent trading day at $55.13, moving +0.35% from the previous trading session. This change outpaced the S&P 500's 0.16% gain on the day. Meanwhile, the Dow gained 0.42%, and the Nasdaq, a tech-heavy index, added 0.03%.

Prior to today's trading, shares of the heart monitoring device maker had lost 19.05% over the past month. This has lagged the Medical sector's loss of 8.18% and the S&P 500's gain of 2.89% in that time.

BEAT will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.43, up 10.26% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $104.29 million, up 10.36% from the prior-year quarter.

BEAT's full-year Zacks Consensus Estimates are calling for earnings of $1.94 per share and revenue of $439.74 million. These results would represent year-over-year changes of 0% and +10.08%, respectively.

Investors should also note any recent changes to analyst estimates for BEAT. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. BEAT is holding a Zacks Rank of #1 (Strong Buy) right now.

Looking at its valuation, BEAT is holding a Forward P/E ratio of 28.28. Its industry sports an average Forward P/E of 19.29, so we one might conclude that BEAT is trading at a premium comparatively.

The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 154, putting it in the bottom 40% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioTelemetry, Inc. (BEAT): Free Stock Analysis Report
To read this article on click here.

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue